| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Excellent Outcomes in Feasibility Study of Radiation-Free Conditioning and Transplant in Pediatric Severe Aplastic Anemia |
|
Transplant Cell Therapy |
Aplastic Anemia |
| Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report |
|
Haematologica |
Aplastic Anemia |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Updates in low/intermediate-risk MDS |
|
The Hematology, ASH Education Program |
Myelodysplastic Syndromes (MDS) |
| The varieties of therapeutic experience: navigating treatment options for patients with PNH |
|
The Hematology, ASH Education Program |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT |
|
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
| Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada |
|
Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
